Pharmaceutical

Image

Global Vaginal Anti Infectives Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Vaginal Anti Infectives Market, By Type (Antifungal, Antibacterial, Antiviral, Others), Product (Creams, Pessaries (Tablets), Gels, Solutions, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Vaginal Anti Infectives Market

Vaginal Anti Infectives Market Analysis and Size

The global vaginal anti infectives market is expected to witness significant growth during the forecast period. Vaginitis is a common type of infection. Bacterial vaginitis, fungal vaginitis (yeast infection), and trichomoniasis are the most frequent kinds of vaginitis. everal reasons can cause vaginal infections such as poor sanitizing condition, unhygienic toilet usage and sexual infection will also boost up the vaginal anti-infectives market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in global vaginal anti infectives market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Vaginal anti-infectives are the type of agents that are used for the killing or supressing the infection of vagina caused by numerous bacteria, virus, fungi or micro-organism. These bacteria and others invade the host by means of its replication or releasing several toxins into the host. "Yeast" infections, tyrichomoniasis vaginitis, bacterial vaginosis, chlamydia vaginitis, and viral vaginitis are the major forms of vaginitis. About one third women all over the world experience indications of vaginitis at some point in their lifetime. Women are highly prone to vaginitis during the reproductive age; a change in the balance of bacteria and yeast present in vagina can lead to vaginitis.

Vaginal Anti Infectives Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Antifungal, Antibacterial, Antiviral, Others), Product (Creams, Pessaries (Tablets), Gels, Solutions, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Perrigo Company plc (U.S.)

Market Opportunities

  • Increased Product Launches
  • Increasing Demand for Retail Pharmacies

Global Vaginal Anti Infectives Market Dynamics

Drivers

  • Increased Strategic Collaborations and Initiatives

Growing inorganics strategies such as business expansion adopted by the numerous market players are expected to boost the growth of the global vaginal anti infectives market during the forecast period. For instance, in June 2016, Bausch Health Companies Inc. announced that its subsidiary Valeant Canada is increasing its manufacturing and export capacity in Canada.

  • Growing Healthcare Facilities

Numerous established healthcare infrastructures, as well as the increased frequency of disease and the occurrence of significant manufacturers, are the primary factors that contributes to the market share. For instance, Gedea created pHyph discovered a pill that helps restore vaginal acidity in the first instance.

Opportunities

  • Increased Product Launches

Major market players in the market are primarily focused on product launches in the market, that is expected to boost the market growth during the forecast period. For instance, in December 2016, Dr. Reddy’s Laboratories Ltd. launched Nystatin and Triamcinolone Acetonide Cream, USP, which the U.S FDA approved .in the U.S. This boosts the market growth.

  • Increasing Demand for Retail Pharmacies

The rise in the number of vaginal anti infectives delivered through retail pharmacies and the increase in the number of retail pharmacies in highly advanced countries create much opportunities for the market growth. In addition, patients choose retail pharmacies to purchase drugs, as these are easily accessible.

 Restraints/Challenges

  • Lack of Awareness about the infection

The lack of awareness about these infections could curb the growth of the global vaginal anti infectives treatment market over a forecast period. Not much awareness about the infection leads to improper treatment thus restraining the market growth.

  • High Cost

The huge expenditure associated with these agents surely hamper the market growth. Several antifungal, antiviral, antibacterial drugs are facing an increasing hike and thus is hampering the market growth.

This global vaginal anti infectives market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vaginal anti infectives market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Vaginal Anti Infectives Market             

The coronavirus pandemic has hindered the development, production, and supply of drugs and other healthcare products and affected numerous companies' growth of healthcare businesses globally. However, in the post-pandmeic era, the market is expected to grow because of an increase in R&D initiatives for exact diagnosis. Numerous government and non-government bodies, including the European Institute of Women's Health (EIWH) and the World Health Organization, have launched multiple public awareness campaigns about women's health.Thus, COVID-19 left a major imapact on the global vaginal anti infectives market.

Global Vaginal Anti Infectives Market Scope

The global vaginal anti infectives market is segmented on the basis of ttype, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Antifungal
  • Fluconazole
  • Clotrimazole
  • Antibacterial
  • Clindamycin
  • Metronidazole
  • Antiviral
  • Others

Product

  • Creams
  • Pessaries (Tablets)
  • Gels
  • Solutions
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Vaginal Anti Infectives Market Regional Analysis/Insights

The global vaginal anti infectives market is analysed and market size insights and trends are provided by type, product, distribution channel and end-user as referenced above.

The major countries covered in the global vaginal anti infectives market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global vaginal anti infectives market throughout the forecasted period due increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and increased prevalence of vaginal infection in women.

North America dominates the market due to increasing initiatives by pharmaceutical organizations to generate novel formulation and well-spread awareness of anti-infectives among end-users. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Vaginal Anti Infectives Market Share Analysis

The global vaginal anti infectives market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global vaginal anti infectives market.

Key players operating in the global vaginal anti infectives market include:

  • Pfizer Inc (U.S.)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Hikma Pharmaceuticals plc (U.K.)
  • Aurobindo Pharma (India)
  • AbbVie Inc. (Ireland)
  • Melinta Therapeutics, Inc (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)
  • Lupin (India)
  • Perrigo Company plc (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

Factors such as increased strategic collaborations and initiatives and growing healthcare facilities are acting as the major drivers for the global vaginal anti infectives market.
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Perrigo Company plc (U.S.).
The major countries covered in the global vaginal anti infectives market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials